-- New Delivery System Will Now Provide RESTASIS ® in a Preservative Free, Easy-to-Use, Multi-Dose Bottle-- -- RESTASIS the Only* Health Canada Approved Treatment to Help Patients Produce More of ...

Topical cyclosporine emulsion 0.05% improved quality of life and proved cost-effective for patients with moderate to severe dry eye syndrome that did not respond to conventional therapy. Dry eye ...

PITTSBURGH, Feb. 3, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the U.S. Food and Drug Administration ...

Please provide your email address to receive an email when new articles are posted on . We interrupt this well-designed linear discussion of dry eye syndrome to bring you an important announcement: ...

The FDA approved the first generic of cyclosporine ophthalmic emulsion (Restasis) for dry eye, a condition that affects millions of Americans each year. Cyclosporine ophthalmic emulsion is a commonly ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. An error has occurred. Please try again ...

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and its subsidiaries today announced that it has reached a settlement regarding its litigation with Famy Care Limited relating to ...

"The Cyclosporine Ophthalmic Emulsion Market 2020 Report aims to provide all the participants and the vendors will all the details about growth factors, shortcomings, threats, and the profitable ...